NEW YORK – The Association for Molecular Pathology (AMP) on Thursday released the preliminary results of its April SARS-CoV-2 testing survey for clinical laboratories, showing that while labs recognize the need to increase diagnostic testing capacity, a significant portion of them have experienced interruptions in their supply chains that have slowed down their ability to offer efficient testing programs to patients.
AMP SARS-CoV-2 Molecular Dx Survey Shows Supply Chain Issues Hampered Ramp Up of Testing
